A Bio-Tech company AVACTA GROUP PLC which develops novel cancer immunotherapies according to their platform trademark Affimer®, has made a major and important announcement that it has entered a collaboration and option agreement with ADC THERAPEUTICS SA.
A clinical-stage biotechnology company pursuing the development and creation of highly potent and targeted antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The agreement is to develop and create Affimer-drug conjugates combining Avacta’s Affimer technology with ADC Therapeutics’ pyrrolobenzodiazepine (PBD)-based warhead and linker technologies. As part of the collaboration, Avacta will generate and optimize Affimer binders against three undisclosed cancer targets and provide these to ADC Therapeutics to target its proprietary cytotoxic warheads (PBDs) to the site of the tumor. ADC Therapeutics will carry out pre-clinical research and development programs to evaluate each of the Affimer-drug conjugates with a view to generating clinical candidates.
Under the terms of the agreement, ADC Therapeutics will cover all Avacta’s costs during the collaboration. Upon ADC Therapeutics entering into each of the commercialization licenses and successfully bringing new Affimer-drug conjugates to market, Avacta will receive option fees, development and commercialization milestones, as well as a single-digit royalty on sales. Further financial details are not disclosed. The two companies are expected to grow on a similar project and the reports said they have planned strategies for taking down rival companies in the quay. The agreement will be beneficial and vital as the new products will be probably a mixture of therapeutics and biotechnology!